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S U M M A R Y
Objectives: The objectives of this study were to characterize isolates of Staphylococcus aureus obtained
from skin and soft tissue infections in the community in Israel and to document the sensitivity patterns
for commonly used antimicrobial agents.
Methods: The susceptibilities of S. aureus isolates from skin and soft tissue infections in the community
in Israel were reviewed to determine the appropriate empirical therapy for these infections.
Results: A total of 7221 isolates were collected during the period 2009–2012; 39% were from children
(age 0–18 years). In children, S. aureus oxacillin resistance dropped from 8.4% to 3.8% (p = 0.073). While
inducible clindamycin resistance increased slightly from 20% to 25%, there was a prominent increase in
constitutive clindamycin resistance from 0.1% to 26.8% (p = 0.012). In adults, oxacillin resistance
increased from 16% to 23% (p < 0.001) and constitutive clindamycin resistance increased notably from
5% to 29% (p < 0.001). These ﬁndings demonstrate a dramatic increase in clindamycin resistance among
S. aureus isolates and suggest against the usage of clindamycin as empirical treatment for suspected S.
aureus infections in Israel.
Conclusions: Beta-lactam anti-staphylococcal agents may be given as empirical treatment for children,
but should be considered according to risk factors for adults in Israel.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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During the past two decades, a steep global rise has been seen in
infections with community-acquired methicillin-resistant Staphy-
lococcus aureus (CA-MRSA) in individuals with no known risk
factors.1–3 Unfortunately, clinical and epidemiological character-
istics cannot distinguish CA-MRSA infection from methicillin-
susceptible S. aureus (MSSA) infection.4
Although there are no data to determine a speciﬁc cut-off
prevalence rate of MRSA infection that warrants a change in
empirical therapy, a prevalence of >15% has been suggested.5 As a
result, in the USA, the use of clindamycin as an alternative empirical
treatment for suspected S. aureus infections rose from 21% in 1999 to
63% in 2008.1 Clindamycin has several advantages—it has both* Corresponding author. Tel.: +972 4 6188452; fax: +972 4 6304955.
E-mail addresses: michal.stein@gmail.com, michals@hy.health.gov.il (M. Stein).
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1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).parenteral and oral formulations, with high bio-availability, good
skin and soft tissue permeability, it inhibits toxin production, and is
relatively cheap.6 Clindamycin has also been used as an alternative
antibiotic for staphylococcal infections in patients with type
1 hypersensitivity to beta-lactam antibiotics. Another optional
treatment for staphylococcal infections is trimethoprim–sulfameth-
oxazole (TMP–SMX), which is also a relatively cheap agent. This anti-
staphylococcal bactericidal treatment is also available in both oral
and parenteral formulations.
Based on a prevalence of resistance of >15% as a guidance for
empirical treatment,5 it is crucial to examine the local epidemiology
in order to optimize the empirical treatment administered in cases of
suspected S. aureus infection. The objectives of this study were to
determine the appropriate empirical treatment for skin and soft
tissue infections (SSTIs) through the characterization of isolates of S.
aureus from SSTIs in the community in Israel and to document their
sensitivities to the following antibiotics by age group: oxacillin,
clindamycin (constitutive and inducible), and TMP–SMX.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 2
MRSA resistance among adults according to age and LTCF residence (2013)
Age (years) Community LTCF
n % n %
18–39 MRSA 15 7 1 6
MSSA 201 93 17 94
Total 216 18
40–69 MRSA 76 18 20 56
MSSA 350 82 16 44
Total 426 36
70 MRSA 76 32 61 73
MSSA 165 68 22 27
Total 241 83
LTCF, long-term care facility; MRSA, methicillin-resistant Staphylococcus aureus;
MSSA, methicillin-susceptible Staphylococcus aureus.
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This retrospective survey was performed in collaboration with
the central laboratory of Maccabi Health Care Services, which
receives specimens and performs all laboratory tests for all of the
Health Maintenance Organization (HMO) patients in the commu-
nity setting throughout Israel. The computerized database of the
central laboratory was reviewed for the characteristics of S. aureus
isolates obtained from SSTIs during the years 2009–2013. The
antibiotic susceptibility patterns of these isolates were documen-
ted. Stratiﬁcation for methicillin resistance among adults was
performed according to age groups and long-term care facility
(LTCF) residence in the last year of the study. Sensitivity testing
was performed using the D-test, as well as with the Vitek
automated system.
Comparisons of the distributions of dichotomous and continu-
ous variables were done with the Chi-square test and Student’s t-
test, respectively. p-Values of <0.05 were considered signiﬁcant.
The study was approved by the ethics committees of Wolfson
Medical Center and Maccabi Health Services, Israel.
3. Results
Using the computerized data system of Maccabi Health
Services, 7221 isolates of S. aureus grown in cultures taken from
SSTIs between January 2009 and November 2012 were reviewed;
2822 of them (39%) were from children aged 0–18 years.
Sensitivity patterns of the isolates to oxacillin and clindamycin
are shown in Table 1.
With regard to methicillin resistance, the prevalence of MRSA in
2009 was 8.4% in children aged 0–18 years; the rate declined
between 2010 and 2012 to 3.8%, however this change was not
statistically signiﬁcant (p = 0.073). In adults aged >19 years, MRSA
prevalence increased from 16% in 2009 to 22–23% during 2010–
2012. This trend was also not statistically signiﬁcant (p = 0.073).
Further stratiﬁcation among adults (Table 2) revealed relatively
low MRSA rates (7%) in patients aged 18–39 years, but higher rates
(18%) among adults 40–69 years of age and in older adults aged
70 years (32%). Higher rates of MRSA were detected in LTCF
residents in the last two age groups (56% and 73% in adults aged
40–69 years and 70 years, respectively).
With regard to the main ﬁndings and trends for clindamycin
resistance, in children aged 0–18 years the prevalence of inducible
clindamycin resistance increased signiﬁcantly from about 19–20%
between 2009 and 2011 to 25% in 2012 (p = 0.04). Moreover, the
increase in constitutive clindamycin resistance was dramatic: from
0.1–2.2% during 2009–2011 to 26.8% in 2012 (p < 0.001). In adults
aged >19 years, the prevalence of inducible clindamycin resistance
was stable over the years and was about 12–16%. However, theTable 1
Sensitivity patterns according to years and age groups
Year Age (years) S. aureus (n) Constitutive
clindamycin
resistance
n 
2009 0–18 1065 1 
>19 1532 77 
2010 0–18 577 11 
>19 857 94 
2011 0–18 627 14 
>19 1030 124 
2012a 0–18 553 148 
>19 906 263 
MRSA, methicillin-resistant Staphylococcus aureus.
a 2012: 11 months.prevalence of constitutive clindamycin resistance showed a similar
increase as found in children, from 5% in 2009 to 11–12% during
2010–2011, and rising to 29% in 2012 (p < 0.001).
Regarding TMP–SMX susceptibility, more than 96% of isolates
in both children and adults were sensitive to TMP–SMX. There
were no signiﬁcant differences between MRSA and MSSA strains in
their resistance to both clindamycin and TMP–SMX.
4. Discussion
Staphylococcus aureus causes a wide range of diseases; it is the
main causative agent of SSTIs such as impetigo, cellulitis, and
cutaneous abscesses. In addition, it causes invasive infections such
as bone and joint infections, pneumonia, sepsis, endocarditis, and
meningitis in rare cases.
The emergence of CA-MRSA strains has become a global
problem and has been particularly prominent in the USA. A
recently published meta-analysis surveyed the CA-MRSA epidemic
in the last two decades and demonstrated a resistance rate ranging
from 50% to 83% in different geographic areas in the USA.7 The rate
of MRSA in all community-associated S. aureus infections in
European countries was found to be 59%,8 while in Asian countries
the reported rates range from 2.5% to 39%.9
In Israel, reports of MRSA rates have varied depending on the
time or methodology: studies on carriage among children have
found a prevalence of 0.8–2.6% of S. aureus isolates.10–12 The
prevalence was found to be somewhat higher (4.8%) in children
hospitalized for S. aureus infections.13 The carriage prevalence
among adults in Israel has been found to be higher than in
children.14 There are no recent data on the prevalence of carriage
or infection of MRSA in adults in Israel.
The growing expansion of CA-MRSA strains has led to the
increased use of alternative anti-staphylococcal drugs, mainlyInducible clindamycin
resistance
MRSA
% n % n %
0.1 215 20.2 89 8.4
5 245 16 245 16
1.8 113 19.7 20 3.5
11 103 12 189 22
2.2 118 18.9 21 3.4
12 124 12 237 23
26.8 136 24.6 21 3.8
29 145 16 208 23
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children hospitalized with S. aureus infection at 25 centers in the
USA over 10 years. They reported an increased incidence of CA-
MRSA from 2 to 21 cases per 1000 admissions, with a simultaneous
increase in clindamycin use for empirical treatment from 21% in
1999 to 63% in 2008.1
There is concern that the increased use of alternative anti-
staphylococcal drugs, mainly clindamycin and TMP–SMX, will
cause selective pressure leading to the spread of strains that are
resistant to these agents. Clindamycin acts by reversible binding to
the 50S subunit of the ribosome, leading to the inhibition of protein
synthesis. The mechanism of resistance of S. aureus to the MLSB
antibiotics (macrolide, lincosamide, streptogramin B) is mediated
through modiﬁcation of the target site of these agents. This
resistance is encoded by the erm gene, usually erm(C) or erm(A),
which encodes the methylation of the 23S rRNA binding site that is
shared by these three drug classes.
Phenotypically, resistance can be expressed constitutively
(MLSBc phenotype) or only when induced into production
following exposure to the antibiotics (MLSBi phenotype; inducible
resistance).15 MLSBc strains are easily recognized as they are
resistant to both macrolides and clindamycin, whereas MLSBi
strains appear to be resistant to macrolides but susceptible to
clindamycin under standard testing conditions. This resistance is
detected by placing an erythromycin susceptibility testing disk in
proximity to a clindamycin disk; the enhanced expression of
resistance among MLSBi strains is expressed by blunting of the
clindamycin zone of inhibition on the zone margin closest to the
erythromycin disk, resembling the shape of the letter D.16
The clinical implications of inducible clindamycin resistance
are unclear. Concerns have been raised regarding the use of
clindamycin in MLSBi infections, especially those that are deep-
seated or with a large bacterial burden, although some patients
will respond clinically to clindamycin therapy. While there is
evidence that constitutive resistance to clindamycin prevents the
inhibition of toxin production and fails to inhibit growth,17 it is
unclear whether inducible clindamycin resistance interferes with
the inhibition of staphylococcal toxin production.15
This study was performed in collaboration with Maccabi
Healthcare Services, the second largest HMO in Israel. Its central
laboratory processes all cultures taken from Maccabi Healthcare
Services patients in community settings throughout Israel.
The prevalence of MRSA previously found in the pediatric
population in Israel was signiﬁcantly lower than those reported in
the USA.7 The present ﬁndings of MRSA prevalence rates of 3–4% out
of all S. aureus strains isolated from SSTIs among children in the
community are in accordance with those of previous studies of the
pediatric population in Israel, which have reported MRSA prevalence
of 2–5% among S. aureus infections leading to hospitalization.10–12
The prevalence of MRSA carriage among adults in the community
setting in Israel was found to be 6.9% in a survey performed in the
early 1990s.14 However, more recent ﬁgures are lacking.
The results of this study indicate that due to the low prevalence
of MRSA among the pediatric population, anti-staphylococcal beta-
lactam antimicrobials are still appropriate as empirical treatment
for suspected staphylococcal infections. In contrast, empirical
treatment with beta-lactams may not be appropriate for older
adults (70 years) and LTCF residents with SSTIs in Israel.
In contrast to the relatively low prevalence of MRSA in the
community, data regarding clindamycin resistance found in this
study are dramatic. For both constitutive and inducible resistance,
this study found 50% prevalence among children and 35% among
adults. This high rate of resistance suggests against the usage of
clindamycin as a single empirical treatment for suspected
staphylococcal infection, whether MRSA or MSSA. The resistance
to clindamycin, especially among children, was not caused byMRSA strains, since the rate of MRSA in children did not increase
during the study period, while clindamycin resistance peaked
dramatically.
A study performed in Israel during 2006–2007, reported
constitutive resistance to clindamycin among 2% and an acquired
resistance among 26% of S. aureus isolates from children in tertiary
care hospitals. These ﬁgures resemble the prevalence rates found
during 2009, the ﬁrst year of the present survey.18
Resistance rates to clindamycin among S. aureus isolates in the
world vary geographically. Abdel Fattah and Darwish reported a
considerable prevalence of constitutive resistance of 13% in
Egypt.19 A study conducted in India during 2010 documented a
prevalence of constitutive resistance of 9% and inducible resistance
of 10% among MSSA strains.20 A prospective study conducted
during 2001–2004 in Texas, USA, found a signiﬁcant increase in
resistance to clindamycin over the 3 years of the study. The
prevalence of clindamycin resistance in MSSA and MRSA was
found to be 11% and 6%, respectively, mostly constitutive.2 A study
from Israel reported a clindamycin resistance rate of 28% among S.
aureus isolates recovered from hospitalized children in a tertiary
medical center during 2006–2007, the large majority (91%) being
inducible resistant strains.18
The present data regarding clindamycin resistance suggest
against its use alone as the ﬁrst choice therapy in patients with
beta-lactam hypersensitivity. It may be used in children in
combination with another anti-staphylococcal agent, such as
TMP–SMX, and an alternative approach is a combination of
macrolide and TMP–SMX.
Another ﬁnding of this study was the relatively low, stable
resistance rate for TMP–SMX among both MSSA and MRSA strains,
ranging between 2% and 4% during the 5 years of the survey. In
contrast to the data regarding clindamycin, this ﬁnding indicates
that TMP–SMX retains its antimicrobial activity against both MSSA
and MRSA and about 97% of these strains are susceptible to this
agent. The combination of TMP and SMX has shown high
bactericidal activity against many bacteria. Furthermore, the
bioavailability of TMP–SMX is relatively high, approximately
85% for both compounds. TMP–SMX is distributed widely
throughout the body, although tissue concentrations are generally
less than serum concentrations.21
Elliott et al. found TMP–SMX to be inferior to anti-staphylo-
coccal beta-lactams and clindamycin for the treatment of SSTIs in a
pediatric population.22 In contrast, it was found to be signiﬁcantly
superior to cephalexin in treating cellulitis.23 Moreover, a study
that compared patients treated with TMP–SMX to those treated
with daptomycin or linezolid, showed TMP–SMX therapy not to be
inferior to these newer antimicrobials in terms of efﬁcacy and
mortality, in addition to being much cheaper.24 Additionally, the
bactericidal activity of TMP–SMX for MRSA was found to be
superior to clindamycin, rifampicin, minocycline, and linezolid.25
However, TMP–SMX has limited activity against group A
Streptococcus (GAS), and this should be taken into consideration
when this agent is used empirically for SSTIs.
This is the ﬁrst nationwide survey to examine the incidence of
MRSA and sensitivity proﬁles of S. aureus isolates in Israel; however
it has several limitations. There could be an upward bias in the
resistances rates, since, in the community setting, cultures are often
taken when there is no response to empirical treatment. However, it
is believed that the high number of isolates included in this survey
reduces the likelihood of this type of bias. Furthermore, this bias
would not affect the data regarding clindamycin resistance, since in
Israel clindamycin is very rarely used as an empirical therapy in the
ambulatory setting. Another limitation is the lack of differentiation
among geographic regions in the country, although Israel is a
geographically small country and it can be assumed that there is no
signiﬁcant variation among these regions.
M. Stein et al. / International Journal of Infectious Diseases 46 (2016) 18–21 21In conclusion, the high rate of clindamycin resistance is
concerning and suggests against the usage of this drug as an
empirical treatment for suspected S. aureus infections in Israel. The
rate of MRSA among the pediatric population in Israel is relatively
low compared to reports from other countries and also to the rates
in Israeli adults. Currently, anti-staphylococcal beta-lactams can
be given as empirical treatment for children, but should be
reconsidered in cases of SSTIs in adult patients in Israel, especially
in older adults (over 70 years old) and/or in adults residing in
LTCFs. The resistance rate to TMP–SMX was found to be relatively
low, thus suggesting it as a therapeutic option that can be given
empirically, especially when MRSA is suspected.
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